Ortho-McNeil, a subsidiary of gigantic healthcare company Johnson & Johnson, makes a variety of women's health and contraceptive products. A division of Ortho-McNeil-Janssen Pharmaceuticals, its women's health line is dominated by oral contraceptives, including Ortho-cyclen, Ortho-novum, and Modicon; other products include Ditropan for overactive bladder treatment and yeast infection drug Terazol. Sister company Ortho-McNeil Neurologics was created to hold Ortho-McNeil's central nervous system drugs, including epilepsy treatment Topamax, pain management drug Ultracet, Alzheimer's treatments, and migraine remedies, allowing the company to focus strictly on women's health.

Sanofi-Aventis Deutschland boasts itself as one of the largest pharmaceutical businesses in the country. A subsidiary of French giant Sanofi-Aventis, the company manufactures and markets prescription and over-the-counter drugs. Along with its Lantus and Insuman insulin products, Sanofi-Aventis Deutschland produces Plavix and Lovenox. The company also dedicates much of its efforts on research and development at its Frankfurt, Germany headquarters and is focused on metabolic illnesses such as diabetes, as well as cancer and cardiovascular diseases.

Fibrocell Science, Inc., a biotechnology company, focuses on developing regenerative fibroblast cells for aesthetic, medical, and scientific applications. The company is developing Azfibrocel-T, an investigational autologous cell therapy to treat nasolabial fold wrinkles. It was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. The company is based in Exton, Pennsylvania.

GeoPharma, Inc. was founded in 1985 and is headquartered in Largo, Florida. GeoPharma, Inc. is engaged in manufacturing, packaging and distributing private label dietary supplements, generic drugs, and health and beauty products under six of its companies, Innovative Health Products, Inc., Libi Labs, Belcher Pharmaceuticals, Inc., American Antibiotics, LLC and EZ-Med. Innovative Health Products and Libi Labs specialize in the development and manufacture of a range of nutritional supplements and cosmeceuticals. Its subsidiaries include Belcher Pharmaceuticals, Inc., Go2PBM Services, Inc., IHP Marketing, Inc., Breakthrough Marketing, Inc., Belcher Capital Corporation, American Antibiotics, LLC, Libi Labs, Inc., EZ-Med Company (EZ-Med) and Dynamic Health Products, Inc. Effective March 31, 2009, the Company discontinued its Distribution segment, which includes Breakthrough Engineered Nutrition.

Adamis Pharmaceuticals Corporation company was founded in 2006 and is based in Del Mar, California. Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company’s wholly owned subsidiary, Biosyn, Inc. has a portfolio of product candidates known as microbicides. Biosyn’s product candidates, which include both contraceptive and non-contraceptive microbicides, are used intravaginally. Biosyn’s product candidates include Savvy, which underwent Phase III clinical trials in Ghana and Nigeria for reduction in the transmission of human immunodeficiency virus/acquired immunodeficiency disease, (HIV/AIDS). Effective April 1, 2009, Cellegy Pharmaceuticals, Inc. merged with Adamis Pharmaceuticals Corporation, pursuant to which Adamis Pharmaceuticals Corporation (Adamis) became a wholly owned subsidiary of the Company.

Eisai develops, manufactures, and distributes prescription pharmaceuticals, primarily in North America and Japan. Prescription drug sales account for a majority of the company's revenues and are led by Aricept, which treats Alzheimer's disease. Other drugs include Myonal, a muscle relaxant, and AcipHex, an acid reflux and ulcer treatment (sold as Pariet in Japan and Europe). Development programs target neurology, oncology, vascular, and immunological ailments. In Japan the company distributes generic and non-prescription drugs and consumer health products. Eisai also makes food additives and chemicals, in addition to drug manufacturing equipment and systems.

Prana Biotechnology Limited (Prana) is a development-stage company at an early stage in the development of its pharmaceutical products that are designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses. Other potential applications for the Company’s therapies include Huntington’s disease, Parkinson’s disease, certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease) and age-related cataracts. The Company has two wholly owned subsidiaries, Prana Biotechnology Inc. and Prana Biotechnology UK Limited. Prana’s activities are focused within Australia and cover research into Alzheimer’s disease and other age-related degenerative disorders.

Advanced Life Sciences Holdings, Inc. company was founded in 1999 and is headquartered in Woodridge, Illinois. Advanced Life Sciences Holdings, Inc., is a biopharmaceutical company focused on the discovery, development and commercialization of drugs in the areas of infectious disease, oncology and respiratory disease. The Company has assembled a pipeline of clinical and preclinical product candidates. In September 2008, the Company entered into a development and commercialization agreement with Wyeth for cethromycin in the Asia Pacific region excluding Japan. Advanced Life Sciences Holdings, Inc. has a worldwide license (excluding Japan) from Abbott Laboratories (Abbott) to develop and commercialize cethromycin, once-a-day antibiotic for the treatment of respiratory tract infections. On September 30, 2008, the Company submitted a new drug application for the use of cethromycin in community acquired pneumonia.

Marshall Edwards, Inc. was founded in 2000 and is based in North Ryde, Australia. Marshall Edwards, Inc. is a subsidiary of Novogen Limited. Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer in the United States and Australia. The company involves in the clinical development and commercialization of its phenoxodiol drug candidates for the treatment of cancer; triphendiol, a signal transduction inhibitor for the treatment of pancreas and bile duct cancers, and melanoma; NV-143, an investigational anti-cancer drug to sensitize melanoma cell lines to the standard of care drug, dacarbazine, and members of the platinum drug family; and NV-128, an investigational cancer compound to promote cancer cell death by targeting the specific protein regulatory pathway in ovarian cancer cells. It is also conducting a Phase II prostate cancer clinical trial using phenoxodiol.

GlaxoSmithKline S.p.A. (GSK Italy), the Italian unit of global pharmaceutical giant GlaxoSmithKline. GSK Italy promotes and sells the therapeutic products of its parent company in the Italian market. The company also makes antibiotics, vaccines, and other injectable drugs at its manufacturing facilities in Parma and Verona, and it has a Milan-based division that sells consumer health care products and over-the-counter drugs. In addition, GSK Italy boasts a research and development unit in Verona that targets neurological drug development, including treatments for depression, addiction, schizophrenia, and sleep disorders.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.